Fundamental Analysis of AXCELLA HEALTH INC(NASDAQ:AXLA) stock

Fundamental Rating

AXLA gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. AXLA may be in some trouble as it scores bad on both profitability and health. AXLA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

AXLA had negative earnings in the past year.

In the past year AXLA has reported a negative cash flow from operations.

In the past 5 years AXLA always reported negative net income.

AXLA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -518.60%, AXLA is doing worse than 98.67% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-518.6%
ROE	N/A
ROIC	N/A

ROA(3y)-197.72%

ROA(5y)-140.01%

ROE(3y)-767.28%

ROE(5y)-495.06%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AXLA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, AXLA has more shares outstanding

The number of shares outstanding for AXLA has been increased compared to 5 years ago.

There is no outstanding debt for AXLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -78.43, we must say that AXLA is in the distress zone and has some risk of bankruptcy.

AXLA's Altman-Z score of -78.43 is on the low side compared to the rest of the industry. AXLA is outperformed by 98.84% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-78.43

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 0.81 indicates that AXLA may have some problems paying its short term obligations.

Looking at the Current ratio, with a value of 0.81, AXLA is doing worse than 92.37% of the companies in the same industry.

A Quick Ratio of 0.81 indicates that AXLA may have some problems paying its short term obligations.

With a Quick ratio value of 0.81, AXLA is not doing good in the industry: 91.71% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.81
Quick Ratio	0.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AXLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.38%, which is quite impressive.

EPS 1Y (TTM)42.38%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%87.5%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AXLA will show a small growth in Earnings Per Share. The EPS will grow by 3.37% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y86.67%

EPS Next 2Y36.63%

EPS Next 3Y22.98%

EPS Next 5Y3.37%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AXLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year AXLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AXLA's earnings are expected to grow with 22.98% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y36.63%

EPS Next 3Y22.98%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AXLA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AXCELLA HEALTH INC

NASDAQ:AXLA (11/22/2023, 8:00:01 PM)

After market: 3.42 -1.16 (-25.33%)

4.58

-0.9 (-16.42%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-14 2023-11-14/bmo

Earnings (Next)03-28 2024-03-28/amc

Inst Owners0%

Inst Owner Change0%

Ins Owners190.4%

Ins Owner Change0%

Market Cap13.51M

Analysts82.5

Price Target15870.1 (346408.73%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)43.83%

Min EPS beat(2)18.3%

Max EPS beat(2)69.36%

EPS beat(4)3

Avg EPS beat(4)23.12%

Min EPS beat(4)-7.84%

Max EPS beat(4)69.36%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)275733%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-2400%

EPS NY rev (1m)0%

EPS NY rev (3m)-2172.73%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-19.25

EYN/A

EPS(NY)-5.1

Fwd EYN/A

FCF(TTM)-14.59

FCFYN/A

OCF(TTM)-14.52

OCFYN/A

SpS0

BVpS-0.75

TBVpS-0.75

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-518.6%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-197.72%

ROA(5y)-140.01%

ROE(3y)-767.28%

ROE(5y)-495.06%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	85.19%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.81
Quick Ratio	0.81
Altman-Z	-78.43

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)86.19%

Cap/Depr(5y)68.29%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)42.38%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%87.5%

EPS Next Y86.67%

EPS Next 2Y36.63%

EPS Next 3Y22.98%

EPS Next 5Y3.37%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y41.49%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y13.15%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y12.77%

OCF growth 3YN/A

OCF growth 5YN/A

AXCELLA HEALTH INC (AXLA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens